tci Medicare Compliance & Reimbursement - 2004 Issue 38

Cardiac Care: CHF Clinics Soon May Lose A Treatment Method

Carriers remove coverage for Natrecor in office setting. Physician offices running congestive heart failure clinics and providing infusions of Natrecor (Nesiritide) should keep an eye on upcoming carrier bulletins.Some carriers have already declared that they won't reimburse J2324 (Injection, nesiritide, 0.5mg) in the office setting, because clinical trials only addressed the treatment's effectiveness in the inpatient setting. These carriers include Cahaba GBA as well as Palmetto GBA, which was paying for Natrecor on a case-by-case basis until recently."Since these patients need to be closely monitored for response to and side effects of treatment, the medical literature...

To read the full article, sign in and subscribe to tci Medicare Compliance & Reimbursement.


Keep pace with evolving Medicare regulations — and onboard your team — with timely analysis of critical updates interpreted in an easy-to-follow, easy-to-apply format. Your subscription to TCI's Medicare Compliance & Reimbursement Alert will equip you to navigate code and guideline changes, CCI edits, and revisions to modifiers, payer policies, the fee schedule, OIG target areas, and more.

  • Current newsletters added each month
  • Fully searchable archives - over 4200 articles
  • ALL years/issues back to 2003 organized by year and issue
  • Codes mentioned in articles are linked to Code Information pages
  • Code Information pages link back to related articles
Access to this feature is available in the following products:
  • tci Medicare Compliance & Reimbursement +Archives

demo
request yours today
subscribe
start today
newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.